Alpha-1 Antitrypsin Deficiency Market Snapshot (2023 to 2033)

The global Alpha-1 antitrypsin deficiency market is likely to garner a market value of USD 3 Billion in 2023 and is expected to reach USD 10 Billion by registering a CAGR of 12.8% in the forecast period 2023 to 2033.

One of the primary reasons driving market expansion is the rising frequency of respiratory illnesses. Furthermore, the increased utilization of augmentation treatment is propelling market expansion.

This therapy includes extracting AAT protein from the blood plasma of a healthy donor in order to increase AAT levels in patients' respiratory tracts. In accordance with this, this treatment also slows the advancement of emphysema, reduces the frequency of exacerbations, and speeds up recovery time, all of which contribute to its growing popularity among both patients and healthcare professionals.

Increased personal disposable income and increased knowledge in developing nations about the availability of treatment choices will provide even more attractive market development potential. Rising worldwide medical tourism, an increase in the prescription for combination medicines, and a high potential for development in the undeveloped market will provide enough market growth possibilities.

Data Points Key Statistics
Expected Market Value (2023) USD 3 Billion
Anticipated Forecast Value (2033) USD 10 Billion
Projected Growth Rate (2023 to 2033) 12.8% CAGR

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Alpha-1 Antitrypsin Deficiency Demand Analysis (2018 to 2022) Vs Market Outlook (2023 to 2033)

The global demand for alpha-1 antitrypsin deficiency is projected to increase at a CAGR of 12.8% during the forecast period between 2023 and 2033, reaching a total of USD 10 Billion in 2033, according to a report from Future Market Insights (FMI). From 2017 to 2022, sales witnessed significant growth, registering a CAGR of 10%.

Numerous technical breakthroughs in diagnostic procedures and the development of novel technologies for the synthesis and purification of AAT. They are of higher grade and devoid of impurities such as viruses and germs. Other factors, such as increased Research and Development efforts and advancements in medical infrastructure, are expected to propel the market even more.

Which are Some Prominent Drivers of Alpha-1 Antitrypsin Deficiency Market?

Increasing Research and Development Activities to Accelerate Market Growth

The increasing number of strategic collaborations between public and private market participants is driving an increase in the amount of Research and Development activities on a daily basis. These capabilities are being applied to the creation of innovative pharmaceuticals and medical technologies, which will drive the need for alpha1-antitrypsin deficiency therapy.

Furthermore, an increase in the number of genetic testing, blood tests, and biopsy tests, increased attempts by public and private groups to raise awareness, and a well-organized distribution network of top manufacturers will all contribute to the market's growth rate. Other factors, such as increased demand for effective medicines and expanding use of early diagnostic methods, will have a beneficial impact on the market's growth rate.

Increasing Healthcare Infrastructure Investment

Another key element impacting the growth rate of the alpha1-antitrypsin market is increased healthcare spending, which aids in infrastructure improvement. The expansion and growth of the healthcare business, particularly in developing nations, would encourage the usage and deployment of new and sophisticated medical technology, equipment, and pharmaceuticals. This will immediately boost the need for therapy of alpha1-antitrypsin deficiency.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Which are the Trough Areas faced by the Alpha-1 Antitrypsin Deficiency Market?

Huge Investments in Research and Development to Stymie Market Augmentation

High expenses connected with research and development capabilities will emerge as one of the market's most significant limitations. The lack of knowledge and necessary infrastructure in developing and backward nations, as well as sluggish diagnostic rates of alpha1-antitrypsin deficiency, may further derail the market expansion. The slow pace of approval for medications and inhibitors, the scarcity of plasma fractionation capacity, and the rising number of patent expirations will all provide challenges to the market's growth rate.

Region-Wise Insights

How will Alpha-1 Antitrypsin Deficiency Market Demand progress in the Asia Pacific?

Rising Healthcare Expenditure to Widen Profit Margins

Asia Pacific encompasses nations with a big patient pool and a high elderly population, thus the alpha1-antitrypsin deficiency industry in that region is driven by this factor. Over the projection period, the Asia Pacific regional sector is predicted to increase at a rapid pace.

The constant development of the medical tourism industry, rising healthcare expenditure, and bigger government initiatives pertaining to the development of healthcare infrastructure, primarily biotechnology, agriculture, and pharmacology, are just a few of the factors contributing to the rapid growth of the Asia Pacific alpha1-antitrypsin deficiency market. As per Future Market Insights, the Asia Pacific is expected to grow at a CAGR of 12% in the assessment period 2023 to 2033.

How attractive are Growth Prospects for Alpha-1 Antitrypsin Deficiency in North America?

Presence of Established Healthcare Infrastructure to Drive Market

The bulk of the worldwide alpha1-antitrypsin deficiency market was accounted for by North America. Because of the growing number of genetic disease therapeutics clinical trials in the area, North America is ruling the alpha1-antitrypsin deficiency market.

The presence of established healthcare infrastructure in the region, the availability of qualified specialists and advanced genetic testing equipment, high healthcare spending, and superior reimbursement rules are key reasons contributing to its substantial share. North America is expected to grow at a CAGR of 12.7% in the assessment period 2023-2033.

What Factors favoring the Growth of Alpha-1 Antitrypsin Deficiency in Europe?

Expanding Patient Pool to fuel Market Growth

Because of the region's abundance of qualified specialists and modern genetic testing equipment, Europe is the second largest market for the alpha1-antitrypsin deficiency industry.

Europe is expected to develop at the fastest rate throughout the projection period owing to an expanding patient pool and more government backing. Thus, owing to the aforementioned reasons, Europe is expected to grow at a CAGR of 12.3% in the assessment period 2023 to 2033.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-Wise Insights

Which is the Most Popular Product Type in the Alpha-1 Antitrypsin Deficiency Market?

Corticosteroid-based Treatments are highly sought after

The increased prevalence of chronic illnesses, an aging population, and rising Research and Development spending are the primary drivers of the corticosteroid segment's rise. The worldwide burden of chronic illnesses is expected to rise dramatically in the future years.

Furthermore, the growing senior population is more prone to chronic diseases that necessitate corticosteroid therapy for a number of ailments, which may drive the corticosteroid sector in the coming years further driving the Alpha-1 Antitrypsin Deficiency market.

Which is the Most Preferred Application in the Alpha-1 Antitrypsin Deficiency Market?

Hospitals to be Primary Centers for Disbursing Treatments

In terms of application, hospitals led the Alpha-1 Antitrypsin Deficiency market in 2022. Patients mostly desire to be admitted to the hospital for therapy.

Moreover, the availability of highly experienced medical personnel who give a superior treatment experience has contributed to the rising market share over the next several years.

Start-Ups for Alpha-1 Antitrypsin Deficiency Market

Key start-up players in the automotive axles are offering new and innovative product lines to consolidate their market presence, these aforementioned start-ups have left no stone unturned. Some specific instances of key Alpha-1 Antitrypsin Deficiency start-ups are as follows:

  • Lexeo Therapeutics, established in the United States, offers gene therapy for degenerative diseases. LX2006, the company's main medication, is an AAV-mediated therapy that treats Friedreich's ataxia (FA), a multi-system illness that affects cardiovascular functioning. LX1004 and LX1001 are two other medicines in the startup's repertoire. The former introduces neuronal ceroid lipofuscinosis 2 (CLN2) into the central nervous system, whereas the latter introduces APOE2. Both medicines are in clinical trials and are aimed towards Batten disease and Alzheimer's disease, respectively.
  • Genespire is an Italian biotech company that is working on gene therapy for hereditary metabolic diseases. X-linked hyper IgM syndrome (X-HIGM) is an uncommon and potentially fatal immunological weakness. The startup's solution uses sophisticated gene editing to combat X-HIGM. This method restores the functional expression of the endogenous faulty gene, enhancing patients' immunological responses. In addition, the company provides lentiviral vector technology for off-the-shelf, in vivo gene therapy for liver ailments.
  • Vivet Therapeutics, a French firm, is developing a gene replacement treatment for Wilson's disease. A mutation in the ATP7B copper transporter causes hazardous copper buildup in the living and central nervous systems. The medicine developed by the company restores physiological copper metabolism by a single intravenous vector injection. This eliminates the need for many daily doses of existing medications. Furthermore, it removes the negative effects associated with existing medication and improves adherence to treatment. The company is also working on treatments for progressive familial intrahepatic cholestasis (PFIC) and Citrullinemia type I (CTLN1).

Market Competition

Key players in the Alpha-1 Antitrypsin Deficiency market are Pfizer, Baxter, AstraZeneca, Grifols, Teva Pharmaceutical Industries, Boehringer Ingelheim, Kamada Ltd, GlaxoSmithKline, CSL Behring, and LFB Biomedicaments.

Recent Developments:

  • In October 2022, Kamada Ltd., a vertically integrated global biopharmaceutical company focused on specialty plasma-derived therapeutics, announced that it has been awarded a three-year extension of an existing tender from the Canadian Blood Services (CBS) for the supply of four IgG products, CYTOGAM®, HEPAGAM®, VARIZIG®, and WINRHO® SDF, for an estimated total value of USD 22 Million. This award ensures that such items will continue to be sold on the Canadian market.
  • In May 2022, Boehringer Ingelheim announced that ArisGlobal has acquired its digital invention, BRASS. This data insights engine will be incorporated into ArisGlobal's LifeSphere® technology platform as LifeSphere Clarity and will play a critical role in driving industry-wide progress of pharmacovigilance and patient safety.

Report Scope

Report Attribute Details
Market Value in 2023 USD 3 Billion
Market Value in 2033 USD 10 Billion
Growth Rate CAGR of 12.8% from 2023 to 2033
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in USD Billion and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered Product, Application, Region
Regions Covered North America; Latin America; Europe; Asia Pacific; Middle East and Africa (MEA)
Key Countries Profiled The USA, Canada, Brazil, Mexico, Germany, The UK, France, Spain, Italy, China, Japan, South Korea, Singapore, Thailand, Indonesia, Australia, New Zealand, GCC, South Africa, Israel
Key Companies Profiled Pfizer; Baxter; AstraZeneca; Grifols; Teva Pharmaceutical Industries; Boehringer Ingelheim; Kamada Ltd; GlaxoSmithKline; CSL Behring; LFB Biomedicaments
Customization Available Upon Request

Key Segments Profiled in the Alpha-1 Antitrypsin Deficiency Market Industry Survey

By Product Type:

  • Augmentation Therapy
  • Bronchodilators
  • Corticosteroids
  • Oxygen Therapy

By Application:

  • Hospitals
  • Specialty Clinics
  • Pharmacies

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa (MEA)

Frequently Asked Questions

What is the anticipated growth of the Alpha-1 Antitrypsin Deficiency market until 2033?

FMI projects the global Alpha-1 Antitrypsin Deficiency market to expand at a 12.8% value CAGR by 2033

What is the estimated market value of Alpha-1 Antitrypsin Deficiency market expected in 2023?

The global Alpha-1 Antitrypsin Deficiency market is estimated at a market value of USD 3 Billion

What is the estimated market value of Alpha-1 Antitrypsin Deficiency market expected in 2033?

The global Alpha-1 Antitrypsin Deficiency market is expected to garner a market value of USD 10 Billion

Which region is forecast to be the most lucrative for Alpha-1 Antitrypsin Deficiency market growth?

As per Future Market Insights, the Asia Pacific is expected to grow at a CAGR of 12% in the assessment period 2023 to 2033.

Which are some prominent Alpha-1 Antitrypsin Deficiency manufacturers?

Pfizer, Baxter, AstraZeneca, Grifols, Teva Pharmaceutical Industries, Boehringer Ingelheim, Kamada Ltd, GlaxoSmithKline, CSL Behring, and LFB Biomedicaments are some prominent Alpha-1 Antitrypsin Deficiency manufacturers.

What is the expected market share of North America in the Alpha-1 Antitrypsin Deficiency market?

North America is expected to grow at a CAGR of 12.7% in the assessment period 2023 to 2033.

What is the expected market share of Europe for Alpha-1 Antitrypsin Deficiency?

Europe is expected to grow at a CAGR of 12.3% in the assessment period 2023 to 2033.

Which Application is expected to hold the largest market share for Alpha-1 Antitrypsin Deficiency in the forecast period 2023 to 2033?

The hospital segment is expected to hold the largest market share for Alpha-1 Antitrypsin Deficiency in the forecast period 2023 to 2033.

Table of Content
	1. Executive Summary
	2. Market Overview
	3. Market Background
	4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
	5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product
		5.1. Augmentation Therapy
		5.2. Bronchodilators
		5.3. Corticosteroids
		5.4. Oxygen Therapy
	6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application
		6.1. Hospitals
		6.2. Specialty Clinics
		6.3. Pharmacies
	7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
		7.1. North America
		7.2. Latin America
		7.3. Europe
		7.4. Asia Pacific
		7.5. Middle East & Africa (MEA)
	8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
	9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
	10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
	11. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
	12. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
	13. Key Countries Market Analysis
	14. Market Structure Analysis
	15. Competition Analysis
		15.1. Pfizer
		15.2. Baxter
		15.3. AstraZeneca
		15.4. Grifols
		15.5. Teva Pharmaceutical Industries
		15.6. Boehringer Ingelheim
		15.7. Kamada Ltd
		15.8. GlaxoSmithKline
		15.9. CSL Behring
		15.10. LFB Biomedicaments
	16. Assumptions & Acronyms Used
	17. Research Methodology
Recommendations

Healthcare

Liver Transplantation Market

September 2023

REP-GB-1281

317 pages

Healthcare

COPD Therapeutics Market

August 2023

REP-GB-4337

342 pages

Healthcare

Lung Disease Therapeutics Market

July 2023

REP-GB-4290

306 pages

Healthcare

Airway Disease Treatment Market

October 2022

REP-GB-3263

342 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Alpha-1 Antitrypsin Deficiency Market

Schedule a Call